Stock Price & Analysis

Buy ARGX stock as strong analyst upgrades, positive sales forecasts for Vyvgart, and favorable technical indicators suggest significant growth potential. The stock is well-positioned to benefit from expanding market share and robust clinical data.

The price prediction for ARGX stock in 2025 is $700, driven by strong Vyvgart sales and positive analyst upgrades.

The S1 support level for ARGX Stock is $572.26 ,The R1 resistant level for ARGX Stock is $615.48.

As of the end of day on 2025-04-02, the price of ARGX Stock was $584.64.

The target price for ARGX Stock according to analyst rating is 751.89, with the highest price target at 1,100 and the lowest at 600.00. Analysts have a Strong Buy rating on ARGX Stock overall.

The market cap of ARGX is $35.5B.

Analysis and Insights

Valuation Metrics:

ARGX's current price of $609.95 reflects strong growth potential, supported by a price target increase to EUR 755 (approximately $817) by Bernstein, driven by Vyvgart's sales forecast of $11 billion by 2030. The EV/EBITDA ratio of 17.77 indicates a premium valuation, while the PS ratio of 6.03 and PB ratio of 17.57 suggest moderate to high valuation levels compared to industry peers.

Market Sentiment and Analyst Ratings:

Analysts have a positive outlook on ARGX, with multiple Buy ratings and price target increases, highlighting confidence in Vyvgart's market potential. The stock's one-year high of $678.21 and low of $349.86 demonstrate significant growth potential.

Clinical Data and Growth Prospects:

Recent clinical trial data for Vyvgart and Vyvgart Hytrulo showed sustained efficacy and safety, reinforcing ARGX's position in autoimmune treatments. This data, presented at the American Academy of Neurology meeting, supports long-term growth and market expansion.

Conclusion:

ARGX is fairly valued given its strong growth prospects and positive analyst sentiment. The stock is not overvalued, as its price reflects the company's potential driven by Vyvgart's success.

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

The price prediction for ARGX stock in 2030 is approximately $900, driven by the strong growth of Vyvgart and its expanding pipeline. Analysts expect significant revenue increases, with Vyvgart potentially becoming a top autoimmune drug.

ARGX has a total of 1148 employees.